AXSM Axsome Therapeutics Inc.

5.40
+0.30  (6%)
Previous Close 5.10
Open 5.15
Price To book 5.63
Market Cap 127499222
Shares 23,610,967
Volume 158,409
Short Ratio 5.09
Av. Daily Volume 155,242

SEC filingsSee all SEC filings

  1. 8-K - Current report 171088968
  2. 8-K - Current report 171079089
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171019928
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018573
  5. 8-K - Current report 171018027

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 initiation announced July 17, 2017.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes

SEC Filings

  1. 8-K - Current report 171088968
  2. 8-K - Current report 171079089
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171019928
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018573
  5. 8-K - Current report 171018027
  6. 8-K - Current report 17983073
  7. 8-K - Current report 17969926
  8. 8-K - Current report 17955233
  9. 8-K - Current report 17918593
  10. 8-K - Current report 17888556